Derm In The News: December 10-16

Aptar: Aptar Digital Health Announces Immuno-Dermatology Partnership with Legit.Health

Aptar Digital Health has announced a strategic partnership with Legit.Health, an AI-based medical device software company. Legit.Health's advanced technology, designed to diagnose around 300 skin conditions, including atopic dermatitis, psoriasis, and skin cancer, will be integrated into Aptar's Digital Health proprietary platform. he AI technology monitors disease progression through validated scoring systems and provides precise measures of disease severity.

CBS News: Moderna-Merck vaccine cuts odds of skin cancer recurrence in half, study finds

Moderna and Merck report promising results in treating advanced melanoma, the deadliest form of skin cancer, with their combined mRNA vaccine and Keytruda. In a trial with 157 patients, those receiving the combination were 49% less likely to die or experience cancer recurrence after three years compared to those on Keytruda alone. The FDA has designated the treatment as a breakthrough therapy, expediting its development for life-threatening diseases.

China Daily: German dermatologist hails value of skin disease research from China

During the 18th Annual Meeting of the China Dermatologist Association and National Congress of Cosmetic Dermatology in Shanghai, Professor Stephan Weidinger from the Christian-Albrechts-University in Germany praised the value of skin disease research from China. He emphasized the significance of large-scale studies conducted in China due to its substantial population. Weidinger expressed interest in collaborating with Chinese researchers, proposing joint projects to identify common and less common subtypes of atopic dermatitis in both China and Germany. The collaboration aims to improve treatment selection as targeted treatments evolve.

Reuters: US FDA approves Arcutis' drug to treat chronic skin disease

The FDA has approved Arcutis Biotherapeutics' drug, roflumilast foam, for treating seborrheic dermatitis in individuals aged 9 and above. This marks the first topical treatment for moderate to severe seborrheic dermatitis with a new mechanism of action in over 2 decades. The foam formulation, known as Zoryve, demonstrated a success rate of 79.5% in late-stage trials, outperforming the placebo. Arcutis plans to launch Zoryve commercially by the end of January, with expectations of coverage by major pharmacy benefit managers.

Read Dermatology Times' coverage of this approval here.

Outsourcing Pharma: Enrollment complete for Lindus Health and Thirty Madison's pilot dermatology study

UK-based Lindus Health and US-based Thirty Madison announced they have completed the enrolment of a trial to assess their personalized dermatology telemedicine platform, Facet.

Have you seen any dermatology headlines this week that we may have missed? Share with us by emailing our team at DTEditor@mmhgroup.com.